Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEONASDAQ:ALKSNASDAQ:MEDPNASDAQ:OMCL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.90+0.6%$6.03$3.93▼$7.32$300.29M1.51695,611 shs372,932 shsALKSAlkermes$28.75-0.9%$30.10$22.90▼$36.45$4.78B0.441.73 million shs1.12 million shsMEDPMedpace$321.50-1.4%$303.28$250.05▼$459.77$9.37B1.47373,876 shs175,561 shsOMCLOmnicell$29.56-0.8%$29.20$22.66▼$55.75$1.40B0.76563,657 shs185,031 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+0.58%+0.07%-5.84%+30.62%+35.72%ALKSAlkermes-0.86%-0.28%-8.06%-4.36%+18.65%MEDPMedpace-1.39%+4.79%+5.04%+11.98%-20.24%OMCLOmnicell-0.81%+2.49%-4.71%-9.58%+10.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics4.0463 of 5 stars3.52.00.04.51.92.50.0ALKSAlkermes4.913 of 5 stars4.43.00.04.22.82.51.9MEDPMedpace4.4617 of 5 stars2.12.00.04.62.14.22.5OMCLOmnicell2.6983 of 5 stars3.32.00.00.02.31.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 3.00Buy$19.25226.05% UpsideALKSAlkermes 2.83Moderate Buy$40.0039.13% UpsideMEDPMedpace 2.21Hold$344.827.25% UpsideOMCLOmnicell 2.57Moderate Buy$44.8351.67% UpsideCurrent Analyst Ratings BreakdownLatest ALKS, ABEO, MEDP, and OMCL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025MEDPMedpaceBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Equal Weight$300.006/17/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$33.00 ➝ $42.006/2/2025ABEOAbeona TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$19.005/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/23/2025OMCLOmnicellPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/23/2025OMCLOmnicellBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$30.00 ➝ $34.005/23/2025OMCLOmnicellWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$35.00 ➝ $37.005/16/2025ABEOAbeona TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $20.005/15/2025ABEOAbeona TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/14/2025OMCLOmnicellWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$31.00 ➝ $35.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M86.30N/AN/A$1.01 per share5.85ALKSAlkermes$1.56B3.04$2.63 per share10.94$9.05 per share3.18MEDPMedpace$2.11B4.38$13.76 per share23.37$26.56 per share12.10OMCLOmnicell$1.11B1.24$3.03 per share9.74$26.84 per share1.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M-$1.27N/AN/AN/AN/A-118.82%-52.48%8/11/2025 (Estimated)ALKSAlkermes$367.07M$2.0913.7620.991.8023.30%27.52%17.98%7/23/2025 (Estimated)MEDPMedpace$404.39M$13.1024.5423.545.8819.31%54.36%20.81%7/21/2025 (Confirmed)OMCLOmnicell$12.53M$0.4664.2623.84N/A1.87%4.60%2.56%7/30/2025 (Estimated)Latest ALKS, ABEO, MEDP, and OMCL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/23/2025Q2 2025ALKSAlkermes$0.42N/AN/AN/A$343.20 millionN/A7/21/2025Q2 2025MEDPMedpace$3.01N/AN/AN/A$537.70 millionN/A5/15/2025Q1 2025ABEOAbeona Therapeutics-$0.35-$0.24+$0.11-$0.24N/AN/A5/6/2025Q1 2025OMCLOmnicell$0.16$0.26+$0.10-$0.15$260.18 million$269.67 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million4/21/2025Q1 2025MEDPMedpace$3.06$3.67+$0.61$3.67$528.38 million$558.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AALKSAlkermesN/AN/AN/AN/AN/AMEDPMedpaceN/AN/AN/AN/AN/AOMCLOmnicellN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.274.904.90ALKSAlkermesN/A3.332.92MEDPMedpaceN/A0.730.73OMCLOmnicell0.131.381.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%ALKSAlkermes95.21%MEDPMedpace77.98%OMCLOmnicell97.70%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics6.90%ALKSAlkermes4.40%MEDPMedpace20.30%OMCLOmnicell2.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A51.16 million47.63 millionOptionableALKSAlkermes1,800164.90 million157.65 millionOptionableMEDPMedpace5,90028.74 million22.91 millionOptionableOMCLOmnicell3,67046.84 million45.66 millionOptionableALKS, ABEO, MEDP, and OMCL HeadlinesRecent News About These CompaniesOmnicell, Inc. (NASDAQ:OMCL) Shares Sold by Sumitomo Mitsui Trust Group Inc.July 2 at 4:33 AM | marketbeat.comOmnicell’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJune 27, 2025 | finance.yahoo.comOmnicell, Inc. (NASDAQ:OMCL) Receives $44.83 Average Price Target from AnalystsJune 25, 2025 | americanbankingnews.com3 Cash-Heavy Stocks Facing HeadwindsJune 24, 2025 | finance.yahoo.comEquities Analysts Offer Predictions for Omnicell Q2 EarningsJune 23, 2025 | marketbeat.comOmnicell, Inc. (NASDAQ:OMCL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 22, 2025 | marketbeat.comExchange Traded Concepts LLC Lowers Stock Position in Omnicell, Inc. (NASDAQ:OMCL)June 19, 2025 | marketbeat.comQ1 Rundown: Omnicell (NASDAQ:OMCL) Vs Other Healthcare Technology for Providers StocksJune 17, 2025 | msn.comGAMMA Investing LLC Has $1.51 Million Holdings in Omnicell, Inc. (NASDAQ:OMCL)June 15, 2025 | marketbeat.comDo Options Traders Know Something About Omnicell Stock We Don't?June 13, 2025 | msn.comOmnicell to pay $4.3M for overbilling VA in SpokaneJune 11, 2025 | khq.comK1 Cash-Producing Stock with Promising Prospects and 2 to Keep Off Your RadarJune 9, 2025 | msn.comIs it Apt to Retain Omnicell Stock in Your Portfolio Now?June 6, 2025 | zacks.comOmnicell, Inc. (NASDAQ:OMCL) Sees Significant Decrease in Short InterestJune 5, 2025 | marketbeat.comOmnicell CFO Nchacha Etta to Step DownJune 5, 2025 | tipranks.comOmnicell (OMCL) Up 27% Since Last Earnings Report: Can It Continue?June 5, 2025 | zacks.comWhat Analysts Are Saying About Omnicell StockMay 23, 2025 | benzinga.comOmnicell (OMCL): B of A Securities Raises Price Target to $34 | OMCL Stock NewsMay 23, 2025 | gurufocus.comOmnicell (OMCL) Target Price Increased Following Share Buyback News | OMCL Stock NewsMay 23, 2025 | gurufocus.comOmnicell Shares Rise on Revised Guidance Following Reduced TariffsMay 22, 2025 | marketwatch.comWhy Omnicell (OMCL) Stock Is Trading Up TodayMay 22, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseChina Market Movers: MCHI, PDD, BIDU Show Bullish TrendsBy Gabriel Osorio-Mazilli | June 16, 2025View China Market Movers: MCHI, PDD, BIDU Show Bullish TrendsTariff Talks Advance, What Taiwan Semiconductor Can DeliverBy Gabriel Osorio-Mazilli | June 16, 2025View Tariff Talks Advance, What Taiwan Semiconductor Can DeliverALKS, ABEO, MEDP, and OMCL Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.90 +0.03 (+0.58%) Closing price 07/3/2025 03:18 PM EasternExtended Trading$5.90 -0.01 (-0.15%) As of 07/3/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Alkermes NASDAQ:ALKS$28.75 -0.25 (-0.86%) Closing price 07/3/2025 03:26 PM EasternExtended Trading$28.75 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Medpace NASDAQ:MEDP$321.50 -4.53 (-1.39%) Closing price 07/3/2025 02:02 PM EasternExtended Trading$321.18 -0.32 (-0.10%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.Omnicell NASDAQ:OMCL$29.56 -0.24 (-0.81%) Closing price 07/3/2025 02:32 PM EasternExtended Trading$29.56 +0.00 (+0.00%) As of 07/3/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
